Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center, shared a post on X:
“Excellent rebuttal by Vamsi Velcheti on why MARIPOSA (amivantamab+lazertinib) is a better 1stLine EGFR lung cancer option from a precision medicine perspective- addressing resistance biology and not only cytoreduction to drive survival.”
More posts featuring MLS-DC25.
